A series of novel sensitizers were successfully synthesized utilizing azobenzene as a π‐linkage unit for the D–π–A structure. A slight red shift on the absorption spectra and λonset of the sensitizers could be observed when the thienyl group was introduced to the acceptor moiety (A). In addition, replacing the donor moiety (D) from carbazole to diarylamino could lead to a negative shift (approximately 0.3 V) in the first oxidation potential. DFT calculation was also carried out and the trend of calculated HOMO–LUMO gaps was consistent to the experimental data obtained from the CV results (DT1 < DT2 < DT3 < DT4). These sensitizers were then employed in dye‐sensitized solar cells to investigate their photovoltaic performances. Highest power conversion efficiency (PCE) of 0.84% was achieved for DT1‐based DSSC according to its most bathochromic absorption spectrum.
BackgroundOver the last 15 years, hand, foot, and mouth disease (HFMD) has emerged as a major public health burden across the Asia-Pacific region. A small proportion of HFMD patients, typically those infected with enterovirus 71 (EV71), develop brainstem encephalitis with autonomic nervous system (ANS) dysregulation and may progress rapidly to cardiopulmonary failure and death. Although milrinone has been reported to control hypertension and support myocardial function in two small studies, in practice, a number of children still deteriorate despite this treatment. Magnesium sulfate (MgSO4) is a cheap, safe, and readily available medication that is effective in managing tetanus-associated ANS dysregulation and has shown promise when used empirically in EV71-confirmed severe HFMD cases.Methods/DesignWe describe the protocol for a randomized, placebo-controlled, double-blind trial of intravenous MgSO4 in Vietnamese children diagnosed clinically with HFMD plus ANS dysregulation with systemic hypertension. A loading dose of MgSO4 or identical placebo is given over 20 min followed by a maintenance infusion for 72 h according to response, aiming for Mg levels two to three times the normal level in the treatment arm. The primary endpoint is a composite of disease progression within 72 h defined as follows: development of pre-specified blood pressure criteria necessitating the addition of milrinone, the need for ventilation, shock, or death. Secondary endpoints comprise these parameters singly, plus other clinical endpoints including the following: requirement for other inotropic agents; duration of hospitalization; presence of neurological sequelae at discharge in survivors; and neurodevelopmental status assessed 6 months after discharge. The number and severity of adverse events observed in the two treatment arms will also be compared. Based on preliminary data from a case series, and allowing for some losses, 190 patients (95 in each arm) will allow detection of a 50 % reduction in disease progression with 90 % power at a two-sided 5 % significance level.DiscussionGiven the large numbers of HFMD cases currently being seen in hospitals in Asia, if MgSO4 is shown to be effective in controlling ANS dysregulation and preventing severe HFMD complications, this finding would be important to pediatric care throughout the region.Trial registrationClinicalTrials.gov Identifier: NCT01940250 (Registered 22 August 2013).Electronic supplementary materialThe online version of this article (doi:10.1186/s13063-016-1215-6) contains supplementary material, which is available to authorized users.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.